Total Holdings
22
Portfolio diversification across 22 positions
THNR
(NYSEARCA)Amplify Weight Loss Drug & Treatment ETF
$25.67-- (--)
Loading... - Market loading
THNR ETF Holdings: Amplify Weight Loss Drug & Treatment ETF
Complete portfolio holdings with allocation weights, sector breakdown, and geographic exposure for this Equity ETF. Analyze fund diversification and concentration.
Assets Under Management
$4.14M
Total fund assets
Expense Ratio
0.59%
Annual management fee
Fund Issuer
Amplify Investments
NYSEARCA
Portfolio Allocations
Distribution breakdown by sector, asset type, and geographic region. Understand the fund's diversification strategy across markets and asset classes.
Loading chart...
Top 26 Holdings by Portfolio Weight
View ticker symbols, company names, asset types, and allocation percentages for each position
Scroll to see more
| # | Symbol | Name | Type | Weight |
|---|---|---|---|---|
| 1 |  | Eli Lilly and Company | Stock | 14.48% |
| 2 |  | Novo Nordisk A/S | Stock | 14.45% |
| 3 |  | Amgen Inc. | Stock | 6.43% |
| 4 |  | Regeneron Pharmaceuticals, Inc | Stock | 6.26% |
| 5 |  | Arrowhead Pharmaceuticals, Inc | Stock | 6.00% |
| 6 | T TSE:4519 | Chugai Pharmaceutical Co. Ltd. | Stock | 5.77% |
| 7 | H HKG:1801 | Innovent Biologics Inc | Stock | 5.64% |
| 8 | T TYO:4519 | Chugai Pharmaceutical Co., Ltd. | Stock | 5.17% |
| 9 | S SWX:ROP | Roche Holding AG | Stock | 5.10% |
| 10 |  | Merck & Co., Inc. | Stock | 5.07% |
| 11 |  | AbbVie Inc. | Stock | 4.99% |
| 12 |  | Pfizer Inc. | Stock | 4.81% |
| 13 | L LSE:AZN | AstraZeneca PLC | Stock | 4.66% |
| 14 | H HKG:1093 | CSPC Pharmaceutical Group Limited | Stock | 4.66% |
| 15 | L LON:AZN | AstraZeneca PLC | Stock | 4.59% |
| 16 | T TSE:4507 | Shionogi & Co. Ltd. | Stock | 4.43% |
| 17 | T TYO:4507 | Shionogi & Co., Ltd. | Stock | 3.89% |
| 18 |  | Scholar Rock Holding Corp | Stock | 2.23% |
| 19 |  | Viking Therapeutics Inc | Stock | 2.14% |
| 20 |  | Structure Therapeutics Inc. | Stock | 1.80% |
| 21 | C CO:ZEAL | Zealand Pharma A/S | Stock | 1.80% |
| 22 | C CPH:ZEAL | Zealand Pharma A/S | Stock | 1.77% |
| 23 | M MUTF:AGPXX | Invesco Short-Term Investments Trust Government & Agency Portfolio Institutional Class | Stock | 1.06% |
| 24 | O OTC:JNGHF | Jiangsu Hengrui Pharmaceuticals Co.,Ltd | Stock | 1.05% |
| 25 | K KRX:128940 | Hanmi Pharm. Co., Ltd. | Stock | 1.03% |
| 26 | N NMFQS:AGPXX | Short-Term Investment Trust - Invesco Government & Agency Portfolio | Cash | 0.90% |
Frequently Asked Questions About Amplify Weight Loss Drug & Treatment ETF Holdings
What are the top holdings in THNR?
Amplify Weight Loss Drug & Treatment ETF (THNR) holds 22 securities. View the complete list of top holdings sorted by portfolio weight, showing each security's ticker symbol, company name, asset type, and allocation percentage.
How concentrated is THNR's portfolio?
Portfolio concentration is measured by the weight of top holdings. A concentrated portfolio has fewer large positions with higher individual weights, while a diversified portfolio distributes holdings more evenly. Review THNR's holdings table to analyze concentration risk.
What is THNR's sector allocation?
The Sector Allocation chart shows how THNR distributes investments across different industries like Technology, Healthcare, Financials, and more. This sector exposure helps understand the fund's industry diversification strategy.
What countries does THNR invest in?
THNR's geographic exposure is shown in the Countries tab under Portfolio Allocations. This reveals the fund's international diversification and exposure to different regions and global markets.
How diversified is THNR ETF?
THNR's diversification can be assessed by reviewing its 22 holdings, sector allocation, and geographic exposure. A well-diversified ETF spreads investments across multiple securities, sectors, and regions to reduce concentration risk.